JPMorgan Chase & Co. Lowers Informa (LON:INF) Price Target to GBX 1,330

Informa (LON:INF) had its price objective lowered by analysts at JPMorgan Chase & Co. from GBX 1,345 to GBX 1,330 in a report released on Monday, Marketbeat.com reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 49.98% from the company’s previous close.

INF has been the subject of a number of other reports. Panmure Gordon reissued a “buy” rating and issued a GBX 1,200 price target on shares of Informa in a research report on Wednesday, November 19th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Informa from GBX 1,000 to GBX 1,140 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Finally, UBS Group reissued a “buy” rating and set a GBX 1,055 price target on shares of Informa in a research report on Friday, November 7th. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of GBX 1,105.

Informa Stock Down 1.6%

Shares of Informa stock traded down GBX 14.20 on Monday, hitting GBX 886.80. The company had a trading volume of 2,321,778 shares, compared to its average volume of 3,303,222. The stock has a market capitalization of £11.34 billion, a price-to-earnings ratio of 161.24, a P/E/G ratio of 0.75 and a beta of 1.12. Informa has a 1 year low of GBX 634.20 and a 1 year high of GBX 1,000. The stock has a 50 day moving average of GBX 918.36 and a 200-day moving average of GBX 897.21. The company has a debt-to-equity ratio of 31.98, a quick ratio of 1.70 and a current ratio of 0.56.

About Informa

Our events, digital products and academic research services connect specialists with knowledge, helping them learn more, know more and do more.

We do this in dozens of specialist markets and subject matter categories, including in Healthcare & Pharma, Technology, Finance, Education, Marketing, Health & Nutrition, Foodservice, and many more.

And we do this through a range of products and services, including major live events, specialist media and content, expert research articles, books and open research platforms, accredited training, buyer discovery services, and digital demand and lead-generation services.